4142:TPE
Adimmune Corp
16,75 NT$
arrow_upward
+0,90%(+0,15) 1 d.
12. nov., 11:17:08 GMT+8 · TWD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 4142…
Atvērt
16,55 NT$
Augsta
16,90 NT$
Zema
16,55 NT$
Tirgus kapitalizācija
7,19 mljrd.
Vid. apjoms
1,14 milj.
Apjoms
287,08 tūkst.
Augstākā 52 ned.
22,50 NT$
Zemākā 52 ned.
15,65 NT$
Peļņa uz vienu akciju
-0,34 NT$
Apgrozībā esošās akcijas
235,29 milj.
Darbinieku skaits
564
Atvērt
16,55 NT$
Augsta
16,90 NT$
Zema
16,55 NT$
Tirgus kapitalizācija
7,19 mljrd.
Vid. apjoms
1,14 milj.
Apjoms
287,08 tūkst.
Augstākā 52 ned.
22,50 NT$
Zemākā 52 ned.
15,65 NT$
Peļņa uz vienu akciju
-0,34 NT$
Apgrozībā esošās akcijas
235,29 milj.
Darbinieku skaits
564
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Eurasia Business News
·
pirms 7 stundām
Stock Market Today: Dow Jones, Nasdaq, S&P 500 Rally on November 11, 2026; Oil Rises, Gold Slips
ChartMill
·
pirms 5 stundām
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session
marketscreener.com
·
pirms 7 stundām
S&P 500's Earnings Growth to Slow in 2027, 2028, UBS Says
Traders Union
·
pirms 4 stundām
Peter Tuchman: S&P 500 gains over $900 billion in market cap, closing up 1.3 percent
Profils
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Par “Adimmune Corp”
Ģenerāldirektors-
Darbinieki564
Dibināšanas datums1965
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietneadimmune.com.tw